Articles by Tom von Gunden

  1. How Formulation Scientists View Drug Delivery With Yogesh Bachhav 9/28/2026

    Videocast host Tom von Gunden talks with Yogeshwar Bachhav, CMC consultant for AiCuris AG Germany, about scientific and technical considerations in the alignment of drug formulations with routes of administration and related delivery systems during product development. Topic coverage includes delivery considerations related to viscosity, permeability, solubility, safety, usability, packaging, and supply chain.

  2. Personalizing LNP-Delivered RNA Payloads At Scale With Acuitas' Ying Tam 9/21/2026

    In this episode of Supplier Horizons, host Tom von Gunden discusses with Chief Scientific Officer Ying Tam from LNP platform developer Acuitas Therapeutics the use of lipid nanoparticles as RNA delivery vehicles across an expanding range of targetable indications, including outside the liver. Among the advances discussed are delivering CAR-T therapies in vivo, loading personalized therapeutic payloads into preformed vesicles, and maintaining RNA stability throughout targeted cellular delivery.

  3. Delivery Considerations For Ophthalmic Targets With Sanner's Rob Henson 9/10/2026

    Rob Henson, Director of Design and Engineering for Sanner US, joins Supplier Horizons host Tom von Gunden to discuss injection devices and other delivery technologies for treating chronic ophthalmic conditions. The topic coverage includes patient safety, device ease-of-use, particulate and endotoxin control, and dose size management in both solid and liquid formulations. 

  4. Investigating Immunogenicity In Sub-Q Delivery With The Subcutaneous Consortium 8/28/2026

    In this episode of In Combination, representatives from the Immunogenicity subteam within industry association The  Subcutaneous Drug Development & Delivery Consortium join host Tom von Gunden to discuss the role and impact of immunogenicity in biotherapeutics product development for sub-Q delivery. Members of the subteam describe the group’s focuses on degrees of desired or acceptable immunogenic response, as well as on industry harmonization of assays employed in preclinical and clinical modeling. 

  5. Managing Logistics For Personalized Therapies With Cryoport Systems' Dominic Clarke 8/21/2026

    In this episode of Supplier Horizons, Dominic Clarke, VP of Technical Operations at specialty supply chain provider Cryoport Systems, joins host Tom von Gunden to discuss logistics practices and challenges in getting CGTs (cell and gene therapies) and other advanced biologics to patients. Using autologous CAR-T therapies as primary example, Clarke describes needs and advances in the collection, transport, manufacturing, cold chain storage, and delivery of personalized medicines. 

  6. Inquiries In Inhalation, Part 2: Having A Nose For Innovation 8/19/2026

    In this follow-up article, Chief Editor Tom von Gunden extends his Part 1 discussion of therapeutic targets for inhaled drugs and biologics into specific aspects of delivery innovation. Among the key considerations are particle engineering, device usability, and the coordination across the ecosystem of inhalation delivery design, development, and distribution. The coverage of advances in device technologies includes inhalers, nebulizers, and nasal sprays. 

  7. Inquiries In Inhalation, Part 1: The Breadth Of Breath 8/12/2026

    In this article, Chief Editor Tom von Gunden considers the expanding range of addressable targets for inhalation drug and biologics delivery. He reports on innovations in oral and nasal inhalation technology that enhance approaches to traditional respiratory indications, as well enable delivery of inhaled therapies to systemic targets beyond the nose and lungs.

  8. Delivering Large Genetic Payloads With SonoThera's Ken Greenberg 7/28/2026

     

    Videocast host Tom von Gunden talks with CEO Ken Greenberg of SonoThera about delivering large payload gene therapies to targeted indications, particularly those requiring redosing. Using Duchenne Muscular Dystrophy {DMD] as primary example, Greenberg describes how ultrasound-mediated, in vivo infusion of naked, or non-encapsulated, DNA to organ targets allows for larger cargo sizes than do vector-based approaches. 

  9. Leveraging Platform Technologies In Drug Delivery With Suttons Creek 7/23/2026

    In this episode of In Combination, Paul Chao and Carolyn Dorgan from combination product and delivery device consultancy Suttons Creek join host Tom von Gunden to discuss strategic considerations and best practices for employing technology platforms in device development for injection-based delivery. The conversation illuminates aspects such as the design space across product assets in development, component options within a platform offering, and regulatory pathways for platform-based submissions. 

  10. Cross-Functional Decisions In Autoinjector Development with Windgap Medical's Aaron Mann 7/21/2026

    On a return videocast appearance, CEO Aaron Mann of autoinjector provider Windgap Medical joins Supplier Horizons host Tom von Gunden to discuss product development decision points around delivering complex molecules via autoinjectors. These cross-functional considerations for drug teams and device teams include high viscosity formulations, device capabilities, product stability, patient safety, and human factors.